Novo Nordisk's Wegovy® (semaglutide) demonstrated significant weight loss averaging 22.6% in premenopausal women and consistent results across all menopause stages, with major reductions in waist circumference. The drug also lowered risks of migraines by 42-45% and depression by 25% compared to menopausal hormone therapy alone. Additionally, Wegovy® reduced cardiovascular risks, including heart attacks and strokes, especially in perimenopausal women. These findings highlight Wegovy®'s potential to improve metabolic health and quality of life for women with obesity during menopause, addressing both physical and mental health challenges.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
